| Name | Title | Contact Details |
|---|
The Chicago Institute for Psychoanalysis is a national leader in psychoanalytic education, scholarship and clinical services to the community. The Institute educates mental health professionals as adult and child psychoanalysts and psychotherapists in its Psychoanalytic Education Program, Adult Psychotherapy Program and Child and Adolescent Psychotherapy Program. Through its clinics, the Institute provides psychotherapy on a sliding scale to adults and children, serving some of Chicago`s most vulnerable and under served communities. It also offers community education programs and consultation to schools, courts, businesses and other organizations. Institute graduates and faculty are highly skilled practitioners of psychoanalysis and psychotherapy and are the teachers, supervisors and consultants to new generations of mental health practitioners.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
In 2016, OmniGuide Surgical and Domain Surgical were merged, creating an organization focused on providing better outcomes and a safer, more seamless surgical experience. Today, OmniGuide Surgical`s Enhanced Safety Flexible CO2 Laser Fibers and Domain Surgical`s FMX Ferromagnetic Technology are used in the most challenging surgical procedures throughout the world, safely delivering energy resulting in the preservation of healthy tissue. OmniGuide Surgical, based in Lexington, MA, USA, is the leader in flexible fiber CO2 laser technology; providing products that enhance surgical accuracy, access, and control for minimally invasive surgery, laparoscopy, and robotic-assisted surgery. Domain Surgical, located in Salt Lake City, UT, USA, provides a patented ferromagnetic technology designed to provide safety and predictability in select surgical procedures that require cutting, coagulating and sealing tissue.
PayLess Drug Stores is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Portland, OR. To find more information about PayLess Drug Stores, please visit www.paylessdrug.com
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.